

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> June 29, 2017	
<b>Re.:</b> Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated June 29, 2017, titled "Zydus' Neshier Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate Extended-Release Capsules".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, Cadila Healthcare Limited



Upen H. Shah  
Company Secretary

Encl.: As above



## **Zydus' Neshor Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate Extended-Release Capsules**

*Ahmedabad, June 29, 2017*

Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Dextroamphetamine Sulfate Extended-Release Capsules, 5 mg. The drug will be produced at the Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA. Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and in the treatment of narcolepsy (a special type of sleep disorder).

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.